Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
Key Highlights
- ➤OP-1 through OP-4 selectively degraded KAT6A with minimal off-target effects
- ➤KAT6A degraders inhibited proliferation across diverse ER+/HER2- breast cancer models
- ➤Monotherapy produced tumor regression in T47D and growth inhibition in MCF7, ST941
- ➤Degraders were well-tolerated across all xenograft study groups
- ➤Good oral bioavailability suggested potential once-daily oral dosing in humans
Expert Statements
David C. Myles, Chief Scientific Officer of Olema Oncology
“We are encouraged by these preclinical findings that support the potential of our highly potent and specific KAT6A degraders as a new therapeutic approach for patients with ER+/HER2- breast cancer”
David C. Myles, Chief Scientific Officer of Olema Oncology
“Taken together with favorable pharmacokinetics and oral bioavailability, the robust antitumor activity observed across both ESR1-mutant and wild-type in vivo models demonstrates their broad potential.”
David C. Myles, Chief Scientific Officer of Olema Oncology
“We look forward to the further evaluation of these KAT6A degraders as we explore broadening our pipeline of novel therapies for breast cancer and beyond to complement our KAT6 inhibitor, OP-3136.”
* Orally bioavailable KAT6A degraders demonstrated potent antiproliferative activity in diverse in vivo models of ER+/HER2- breast cancer * KAT6A degradation was active in both ESR1-mutant and wild-type cell models * Degraders were well-tolerated in all groups SAN FRANCISCO, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preclinical data on a series of selective KAT6A degraders in estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer models. The findings will be presented in a poster session at the 38th EORTC-NCI-AACR (ENA) Symposium, held November 18-20, 2026 in Barcelona, Spain.
“We are encouraged by these preclinical findings that support the potential of our highly potent and specific KAT6A degraders as a new therapeutic approach for patients with ER+/HER2- breast cancer,” said David C. Myles, Ph.D., Chief Scientific Officer of Olema Oncology. “Taken together with favorable pharmacokinetics and oral bioavailability, the robust antitumor activity observed across both ESR1-mutant and wild-type in vivo models demonstrates their broad potential. We look forward to the further evaluation of these KAT6A degraders as we explore broadening our pipeline of novel therapies for breast cancer and beyond to complement our KAT6 inhibitor, OP-3136.”
Get started
Create a free account to read the full story.
